Treatment-related late toxicities after pediatric allogeneic hematopoietic SCT (allo-HSCT) are increasingly important as long-term survival has become an expected outcome for many transplanted children and adolescents. In a retrospective cohort study, we assessed long-term health outcomes in 204 allo-HSCT survivors transplanted in childhood or adolescence (o 20 years) between 1978 through 2000 after a median follow-up time of 12 (range 4-28) years. Data on conditioning regimen, adverse health events (AE) and growth and hormonal substitutions (hormone replacement therapies (HRTs)) were obtained from medical records. AEs were graded retrospectively according to Common Terminology Criteria for Adverse Events v3.0. Late deaths (⩾48 months after allo-HSCT) were evaluated separately. Multivariate analysis demonstrated that chronic GVHD (P o0.000) and longer follow-up time (P o0.05) correlated with AEs, whereas CY-based conditioning was inversely correlated (P o 0.002). TBI and longer follow-up duration predicted more severe AEs (P o 0.001 and P o 0.001, respectively). HRTs were more frequent after TBI. Diabetes type II, dyslipidemia and hypertension were detected in 9, 7 and 7% of the survivors, respectively. Late deaths (n = 22) were most frequently due to pulmonary failure (n = 7), followed by secondary malignancy (n = 5). The occurrence of AEs after pediatric allo-HSCT is high and likely to increase during extended follow-up, particularly in patients who have received TBI.
INTRODUCTION
There has been a significant increase in the number of pediatric allogeneic hematopoietic SCTs (HSCT) since the mid-1990s with decreased transplant-related mortality. 1 The cumulative burden of treatment-related morbidity after childhood HSCT is considerable [2] [3] [4] [5] and seems to increase over time. 6 Conditioning with TBI is a risk factor for late effects when compared with chemotherapy-based conditioning. [2] [3] [4] [5] 7, 8 There is a relatively limited literature evaluating very long-term effects of pediatric HSCT. Most studies have included patients with comparatively short follow-up times, often o 4 years, 6, 9 or been limited by lack of follow-up data into late puberty or adulthood. 10 As long-term survival is an expected outcome for many pediatric patients undergoing HSCT, the treatment-related late toxicities are becoming increasingly important. In a retrospective cohort study, we aimed to evaluate the frequency, spectrum and risk factors of late effects in a cohort of pediatric allogeneic HSCT (allo-HSCT) survivors with longitudinal follow-up data into late puberty or adulthood.
MATERIALS AND METHODS Patients
All long-term survivors who were o20 years old when receiving allo-HSCT for any diagnosis at the pediatric clinics of Karolinska University Hospital Huddinge, Sweden or the Children's Hospital, Helsinki University Central Hospital, Finland between 1978 through 2000 alive ⩾ 4 years after allo-HSCT and at the time of the data collection in 2009-2011 were eligible for the study. The total number of pediatric patients transplanted during this period was 261 in Huddinge and 181 in Helsinki. The study patient characteristics are listed in Table 1 .
Treatment characteristics
Leukemia patients were treated according to the common Nordic protocols (established in 1982 for ALL and in 1984 for AML). 11, 12 Singlefraction TBI (sTBI) 10-12 Gy with CY (120 mg/kg) was used at the University Hospital in Huddinge during 1978-1995 and at the Helsinki University Hospital during [1978] [1979] [1980] [1981] [1982] [1983] . Fractionated TBI (fTBI) was introduced in Helsinki in 1984 (10) (11) (12) Gy in 5-6 fractions) and in Huddinge in 1993 (12 Gy in 4 fractions). Patients with SAA have received CY (200 mg/kg) with or without TLI 6 Gy or fTBI 10 Gy. Patients with immunodeficiencies or congenital metabolic defects have received (BU 16 mg/kg) usually combined with CY (100-200 mg/kg). The conditioning of study patients is presented in Table 1 . The patients were classified into conditioning groups: (1) TBI-based conditioning (TBI), n = 145; (2) BU-based conditioning (BU) without TBI or TLI, n = 30; (3) conditioning with only CY (CY), n = 23; and (4) conditioning with chemotherapy and TLI (TLI), n = 6.
The follow-up program and data collection
The follow-up program consisted, after the first year, initially of biannual and later annual contact at the outpatient clinic, including both clinical and laboratory examinations. Through a detailed retrospective review of medical records, every medical event or chronic health condition after allo-HSCT until the most recent visit was recorded. Information on chronic GVHD (cGVHD), medications and all hormonal substitutions ever used (growth hormone (GH), thyroxine and estrogen or testosterone) was collected. Follow-up time was determined as the time from HSCT to the last recorded evaluation. Non-hormonal late effects were retrospectively graded according to the Common Terminology Criteria for Adverse Events version 3.0. Adverse health events (AEs) that could not explicitly be found in these criteria were graded as follows: Mild changes detected by diagnostic methods but clinically remaining unremarkable were classified as grade 1. Moderate damages needing further intervention (for example, drug therapy) or remaining symptomatic without interfering with activities of daily life, were given grade 2. Late effects needing a more aggressive therapy with hospitalization (for example, surgery) were classified as grade 3. Life-threatening or disabling were classified as grade 4. Psychological issues were not explicitly investigated in this study; information was based on what providers noted in the medical charts. Lansky scores had not been recorded during follow-up and are therefore not reported. Growth and hormonal substitutions were analyzed separately and excluded from the subanalyses comparing the number, and severity, of non-hormonal chronic health conditions. Cataract, a relatively mild and highly prevalent grade 3 AE after TBI, was excluded from analyses comparing AEs after different conditioning regimens, because it might have overstated the severe grade 3-4 late toxicities after TBI.
Height measurements
Adult height was documented by growth velocity o1 cm/year, mature bone age was verified by X-ray or age 418 years at the time of the last measurement. At the most recent evaluation, 165 (81%) had reached an adult height and 161 patients (79%) had complete growth data available. Height measurements were expressed as standard deviation score (SDS) from the mean of the normal population in Sweden. 13 The difference between the height SDS value at SCT and that of the adult height was calculated for each patient and was regarded as the delta-SDS value, expressing the gain (zero or positive values) or the loss of height (negative values) after transplantation in terms of SDS. Statistical analyses for the comparisons of delta-SDS values were performed according to the age and pubertal status at SCT, diagnosis group, gender, CR status at SCT and conditioning regimens.
Statistical analysis
Statistical analyses were performed using the IBM SPSS Statistics, Version 20.0, Armonk, NY, USA. Mann-Whitney U test (for continuous variables), Fisher's exact test and χ 2 test (for categorical variables) were conducted to test differences between the groups. Pearson correlation was used to select explanatory covariates for the step-wise forward regression analysis that was used to model the relationships between dependent variables (multiple hormonal substitutions, number and the severity of nonhormonal chronic health conditions) and the explanatory covariates (gender, pubertal status at HSCT, age at HSCT, cGHVD, follow-up time, SAA group, leukemia group, Others group, sTBI, fTBI, TBI, CY and BU). For the leukemia group, additional covariates were remission status at HSCT, cranial irradiation and testicular irradiation. Six patients who received TLI as the only form of irradiation were excluded from the analyses comparing the conditioning regimens. P-value o0.05 was set to indicate statistical significance. No corrections were made for multiplicity.
Ethics vetting
The Research Ethics Committee of the Helsinki University Central Hospital and the Regional Ethical Review Board in Stockholm approved the study.
RESULTS
Out of the eligible 225 survivors, 204 (91%) had available follow-up data of at least 4 years and were included in the study. Twenty-one patients (9%) were lost to follow-up. Patients (n = 22) who had died ⩾ 48 months after allo-HSCT were not included in the analyses but are reported separately. The study patients were classified into three groups according to their diagnosis and treatment prior to allo-HSCT: (1) the leukemia group, patients with AML (n = 46) and ALL (n = 78); (2) the SAA group, patients with SAA (n = 31); and (3) the Others group, patients with non-malignant disorders (n = 49); immunodeficiencies, congenital metabolic defects; or malignant diseases not given cytotoxic therapy prior to allo-HSCT. The patients were further divided according to their pubertal status at SCT: (1) prepubertal (Tanner 1) and (2) pubertal/ post-pubertal (Tanner 2-5).
Late causes of death Out of the 442 transplanted children, 217 (50%) had died and 22 of these patients died ⩾ 48 months after HSCT, between 64 and 294 months after transplantation. All late causes of death are listed in Table 2 . For these 22 deceased patients, the median age at HSCT was 13 (2-15) years and the median age at death was 17 (10-36) years. Patients with leukemia, n 124 Cranial irradiation for leukemia, n (%) 26 (13) Testicular irradiation for leukemia, n (%)
8 (4) Remission status of leukemia, n (%) CR 1 63 (51) CR 2-4 61 (49)
Abbreviations: fTBI = fractioned TBI; HSCT = hematopoietic SCT; sTBI = single-fraction TBI.
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Non-hormonal chronic health conditions and AEs Out of the 204 survivors, 172 (84%) had at least one non-hormonal chronic health condition and 84 (41%) had at least one grade 3 condition. The non-hormonal chronic health conditions are listed in Table 3 by category; some patients had several conditions within the same category. Cataract was the most common AE found in 80 (39%) of the survivors. Musculoskeletal AEs (24%) and generalized skin involvement (27%) were very common. Twentyone (10%) survivors had cardiac problems, and 18 (9%) had been diagnosed with chronic diabetes mellitus grade 2-3 (all diabetes type 2). Severe, grade 3 or 4, central nervous system-related conditions (like seizures, cognitive disorders and strokes) had been diagnosed in 16 (8%) of the survivors. Eight survivors (4%) had been diagnosed with a secondary malignancy, and all of these patients were recipients of TBI-based conditioning. None of these patients had Fanconi anemia. Almost all of the patients conditioned with BU (97%) and the majority of TBI-recipients (76%) had late AEs, whereas the corresponding figure for the CY-recipients was 61%. The prevalence and severity of non-hormonal chronic health conditions was greater among patients conditioned with TBI or BU when compared with CY ( Figure 1a) . A majority (67%) of the BU-recipients had more than two AEs. A higher prevalence and severity of the AEs was seen in patients with cGVHD (Figure 1b) , prevalence and severity of AEs increased over time ( Figure 1c) and AEs tended to be more frequent among patients with longer follow-up times with the exception of BU (Figure 1d) .
The multivariate analysis for non-hormonal AEs (excluding cataracts) demonstrated that cGVHD and follow-up time impacted both the number and severity of AEs among all patients. Conditioning was an independent predictor of AEs. The CYbased conditioning regimen decreased the risk of several AEs and TBI-based conditioning increased the risk of more severe AEs (Table 4) . In a separate multivariate analysis for leukemia patients, fTBI predicted fewer AEs (β − 0.75, 95% confidence interval (CI), −1.43, −0.08, P o 0.030) and female gender predicted both higher numbers and more severe AEs (β 0.98, 95% CI, 0.30, 1.66, Po 0.005 and β 0.48, 95% CI, 0.02, 0.95, Po 0.043, respectively). A higher CR status (CR ⩾ 2) at HSCT, cranial irradiation (cranial radio therapy), testicular irradiation or age at HSCT had no independent effect on the number or the severity of AEs (not shown).
Hormonal substitutions All substituted hormones ever used are reported in Table 5 . In the multivariate analysis, female gender, being prepubertal at HSCT, TBI-based conditioning and longer follow-up duration independently predicted multiple (⩾2) hormonal substitutions (Table 4) . Female gender was associated with a more frequent use of sex steroids (Table 5) . Prepubertal status at transplantation significantly increased the need of GH and thyroxine substitutions after HSCT. Cranial radio therapy as part of the antileukemia therapy prior to HSCT increased the use of GH and thyroxine (Table 5) . A higher proportion of leukemia patients transplanted in CR ⩾ 2 needed sex steroid substitutions, but otherwise the remission status at SCT did not impact hormonal deficiencies.
Out of the TBI-recipients, 81% needed hormonal substitutions compared with 63% of the BU-recipients. Patients with BU-based conditioning had less GH and sex steroid substitutions than survivors conditioned with TBI, but they required GH and 
Abbreviations: cGVHD = chronic GVHD; HSCT = hematopoietic SCT. Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events.
Adverse health events after pediatric allogeneic HSCT M Wilhelmsson et al thyroxine substitutions more often than survivors with CY ( Table 5 ). Fractionation of TBI decreased the need of GH and thyroxine, whereas the use of sex steroids was similar when compared with sTBI.
Growth impairment Adult height and SDSs are reported in Figure 2 . The leukemia patients suffered the greatest loss in height SDS when compared with patients with SAA and other diagnoses (P o0.001 and P o0.003, respectively). TBI caused greater loss in height SDS when compared with both BU and CY (Po 0.019 and P o 0.001, respectively). Patients transplanted in prepuberty experienced greater height SDS loss and had shorter adult heights than patients transplanted after the onset of puberty (P o0.0001). Only the patients within the Others group had significantly lower height SDS at HSCT when compared with other diagnoses (not shown).
DISCUSSION
We report a high frequency of various late effects in long-term survivors of pediatric allo-HSCT after a median longitudinal followup time of 12 years. Altogether, 85% of the survivors suffered at least one chronic health condition. Among the survivors with the longest follow-up time of ⩾ 20 years, the corresponding figure was 96%. Leukemia survivors, recipients of TBI-based conditioning and survivors with cGVHD were identified as the most vulnerable groups. Consistent with findings from other studies, AEs tended to increase in severity with expanding follow-up time. 6, 14 Of the survivors with the longest follow-up of ⩾ 20 years, 50% had at least one severe or disabling (grade 3-4) late effect. SAA patients had notably lower burdens of late effects, consistent with the report from Sanders et al. 15 SAA patients had not received other cytotoxic therapies prior to HSCT, and majority of them had been conditioned with CY. We conclude that both the less frequent use of BU or TBI in the conditioning regimens as well as the lack of exposure to other cytotoxic agents prior to HSCT explain these more favorable outcomes. Similar to previous studies, the presence of cGVHD was a risk factor for non-hormonal chronic health conditions 14 and can be regarded especially harmful for SAA patients who otherwise have better long-term health prospects.
For decades, TBI has been the most frequently applied myeloablative and immunoablative procedure for patients with leukemia undergoing HSCT. At present, BU is the recommended conditioning regimen for a majority of AML patients who tolerate full conditioning. For high-risk AML patients, TBI may be indicated. The use of TBI has been associated with a superior disease-free survival in very high-risk AML patients with the somatic mutation FMS-like tyrosine kinase 3 internal tandem duplication. 16 In ALL patients, TBI is widely used as it has not been shown that TBI could be replaced by chemotherapy. [17] [18] [19] Since the late 1970s, both TBI therapy and supportive care have greatly improved, and this may result in less frequent late effects among the more recently treated survivors.
In the present study, BU-recipients suffered from a considerable number of non-hormonal AEs; however, their non-hormonal AEs were less severe when compared with TBI. BU also impaired growth less, and compared with TBI-recipients the BU-recipients less often needed hormonal substitutions. Moreover, BU may preserve a higher chance of spermatogenetic recovery, as reported earlier. 20 After extended follow-up, BU seems to be the less toxic myeloablative alternative to TBI and this is supported by other reports. 3, 6, 21, 22 Health conditions that are known to predispose to other, more disabling or life-threatening events were common among the HSCT survivors. Consistent with other studies, 23-25 many of the survivors suffered from metabolic disorders: diabetes type II (9%); dyslipidemia (7%); and hypertension (7%), all well-known risk factors for cardiovascular events. 26 Higher rates of cardiovascular risk factors after HSCT have been reported even in the adult population. 27 These conditions are relatively rare among young adults in the Nordic countries. In Sweden, only 0.6% of the population aged 16-44 years has diabetes type 2. 28 In a previous population-based register study, the Nordic childhood cancer survivors were 1.8 times more likely than the sibling comparison group to report diabetes mellitus. 29 The majority of these survivors were treated with conventional protocols without HSCT. Particularly TBI has been identified as a risk factor for the metabolic syndrome after HSCT. 30, 31 Irradiation 32 and allo-HSCT, particularly if GVHD is present, have been shown to increase the risk for premature arterial vascular disease and poor cardiac function. 23 In the present study, two patients had died at a young adult age, 420 years after receiving TBI, due to acute myocardial infarction and stroke. Cardiovascular late morbidity 33 and an accelerated aging process described in childhood cancer survivors 34 is likely to be more pronounced among the childhood cancer survivors treated with HSCT and this is supported by our findings. Consistent with other reports, 14 a more intensive treatment of relapsed leukemia prior to HSCT (CR ⩾ 2) was not predictive of higher occurrence of non-hormonal health conditions, multiple hormonal substitutions or growth disorders. This may suggest that it is mainly the conditioning regimen and the presence of cGVHD that ultimately determine the burden of these late effects in leukemia survivors who have received allo-HSCT.
Secondary malignancies occurred after TBI-based conditioning, with the exception of one SAA patient diagnosed with tongue cancer. The overall occurrence of secondary malignancies among all patients surviving at least 4 years after HSCT was 5%, and this is comparable with previous studies. 6, 35 Few studies report late deaths after pediatric allo-HSCT. In contrast to previous studies, 6 ,36,37 relapse was not the predominant cause of late deaths, accounting for only three deaths. This discrepancy is probably explained by the study design that only included late deaths occurring Z 48 months after HSCT. Non-relapse-related mortality has been shown to be increased among patients with cGVHD. 37 In this study, pulmonary failure, mainly bronchiolitis obliterans, was the leading cause of death followed by secondary malignancy. Respiratory tract complications are often closely related to cGVHD and have, in many cases, a poor prognosis. 38 The strengths of this study are the detailed and longitudinal follow-up data collected fom high-quality medical records stretching into late puberty or adulthood with a relatively small number of patients lost to follow-up. This study has, however, some limitations. The data were reviewed retrospectively and some milder conditions may have been under-represented and Although both centers had very similar follow-up routines and all the leukemia patients were treated according to the common Nordic leukemia treatment protocols, we cannot completely rule out some differences in the local follow-up routines or changes over time. Some data were harder to obtain. For instance, we were unable to record the cumulative anthracycline doses for cardiac complications in the leukemia patients. Many of the oldest survivors were recipients of the more toxic sTBI; this could exaggerate effects of follow-up time as majority of the survivors with the longest follow-up times, ⩾ 20 years, had received sTBI. However, the number of AEs increased with follow-up time irrespective of the fractionation of TBI and a significant increase in the number of AEs after fTBI was seen between the shorter followup times of 4-9 years vs 10-19 years. This suggests that the change from sTBI to fTBI does not alone explain the higher incidence and severity of AEs.
There are many other potential explanations. Longer observation periods may simply have allowed the detection of very late effects as well as the increase in severity. The more recently treated patients have also received more modern supportive care and antileukemia therapy. Indications for HSCT and conditioning regimens have changed over time. During the early era, BU was only used for non-malignant disease, but since 1996, patients with AML have in increasing numbers received BU instead of TBI. Leukemia patients in the BU group after 1996 may explain the deviating trend in the number of AEs in relation to follow-up time among BU-conditioned patients (Figure 1d ).
In conclusion, the current study confirms the high burden of late toxicities after pediatric allo-HSCT and underlines the importance of extended follow-up, particularly after TBI-based conditioning. The presence of cGVHD was associated with a significant late morbidity, and irreversible lung complications were a frequent cause of late mortality stressing the importance of early detection and intervention of post-transplant pulmonary abnormalities. Cardiovascular risk factors were frequent, indicating that screening, adaptation of lifestyles as well as medical interventions should be initiated early in order to counteract the process of premature arterial ageing. Life-long surveillance after pediatric ( Adverse health events after pediatric allogeneic HSCT M Wilhelmsson et al
